Science Explorer Back to mapMap
Discussion
Company · Suzhou · China

PersonGen (China)

persongen.comROR OpenAlex
Research works
17
▲ 2% vs 2018-21
Citations
322
18.5 per fractional work
Top-10% rate
14.0%
all institutions 10.0%
Open access
53%
world 40%
International
26%
world 18%
PersonGen (China)

Not ranked overall: PersonGen (China) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does PersonGen (China) work in?

In all years, 57% of research at PersonGen (China) is in Health Sciences, 32% in Life Sciences. Its largest fields are Medicine (57%), Biochemistry, Genetics and Molecular Biology (16%), Immunology and Microbiology (15%). It does 1.8× the world's share of Health Sciences.

Health Sciences: 10 fractional works · 56.5% of its workMedicine: 10 fractional works · 56.5% of its workOncology: 6 fractional works · 32.1% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 5.9% of its workHematology: 1 fractional works · 3.5% of its workGenetics: 1 fractional works · 3.3% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 2.8% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 1.9% of its workDermatology: 0 fractional works · 1.4% of its workPathology and Forensic Medicine: 0 fractional works · 1.2% of its workNeurology: 0 fractional works · 1.0% of its workPhysiology: 0 fractional works · 1.0% of its workPulmonary and Respiratory Medicine: 0 fractional works · 1.0% of its workComplementary and alternative medicine: 0 fractional works · 0.6% of its workPharmacology: 0 fractional works · 0.5% of its workSurgery: 0 fractional works · 0.3% of its workLife Sciences: 6 fractional works · 31.9% of its workBiochemistry, Genetics and Molecular Biology: 3 fractional works · 15.7% of its workMolecular Biology: 1 fractional works · 8.1% of its workGenetics: 1 fractional works · 5.0% of its workClinical Biochemistry: 0 fractional works · 1.0% of its workPhysiology: 0 fractional works · 1.0% of its workBiotechnology: 0 fractional works · 0.6% of its workImmunology and Microbiology: 3 fractional works · 15.2% of its workImmunology: 3 fractional works · 15.2% of its workNeuroscience: 0 fractional works · 1.0% of its workNeurology: 0 fractional works · 1.0% of its workPhysical Sciences: 2 fractional works · 9.8% of its workEngineering: 1 fractional works · 5.0% of its workElectrical and Electronic Engineering: 1 fractional works · 4.0% of its workBiomedical Engineering: 0 fractional works · 1.0% of its workComputer Science: 1 fractional works · 3.2% of its workComputer Vision and Pattern Recognition: 1 fractional works · 3.2% of its workChemistry: 0 fractional works · 0.9% of its workAnalytical Chemistry: 0 fractional works · 0.9% of its workMathematics: 0 fractional works · 0.4% of its workStatistics and Probability: 0 fractional works · 0.4% of its workPhysics and Astronomy: 0 fractional works · 0.3% of its workRadiation: 0 fractional works · 0.3% of its workSocial Sciences: 0 fractional works · 1.8% of its workBusiness, Management and Accounting: 0 fractional works · 1.2% of its workManagement of Technology and Innovation: 0 fractional works · 1.2% of its workSocial Sciences: 0 fractional works · 0.6% of its workLaw: 0 fractional works · 0.3% of its workSociology and Political Science: 0 fractional works · 0.3% of its workALL ITS WORKPersonGen (China)17fractional works, all years
Life Sciences32%Physical Sciences10%Health Sciences57%Social Sciences2%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 11 fields, with their numbers
    1. Medicine1056.5%
    1. Biochemistry, Genetics and Molecular Biology315.7%
    2. Immunology and Microbiology315.2%
    3. Neuroscience01.0%
    1. Engineering15.0%
    2. Computer Science13.2%
    3. Chemistry00.9%
    4. Mathematics00.4%
    5. Physics and Astronomy00.3%
    1. Business, Management and Accounting01.2%
    2. Social Sciences00.6%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 2.20× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 18.46× its world share, 2 worksImmunology and Micro…Neuroscience: 1.22× its world share, 0 worksNeuroscienceComputer Science: 0.09× its world share, 0 worksComputer ScienceEngineering: 0.53× its world share, 1 worksEngineeringMathematics: 0.67× its world share, 0 worksMathematicsPhysics and Astronomy: 0.30× its world share, 0 worksPhysics and AstronomyMedicine: 3.00× its world share, 5 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 18.5×. Every wedge is a field page.

All 8 fields, with their numbers
  1. Immunology and Microbiology18.46×2 works
  2. Medicine3.00×5 works
  3. Biochemistry, Genetics and Molecular Biology2.20×1 works
  4. Neuroscience1.22×0 works
  5. Mathematics0.67×0 works
  6. Engineering0.53×1 works
  7. Physics and Astronomy0.30×0 works
  8. Computer Science0.09×0 works

Who are the top researchers at PersonGen (China)?

Ranked on the quality score, Fengtao You lead among researchers whose main affiliation is PersonGen (China).

  1. 1 Fengtao You China · #790,270 worldwide 1.1k citations · 60 works
All ranked researchers at PersonGen (China)

What are the most cited papers from PersonGen (China)?

The most cited paper from PersonGen (China) is "Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia." (Xiaowen Tang, Lin Yang, Zheng Li et al., 2018), with 412 citations. Next come "Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells" (153) and "A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia." (130).

Most cited papers
#PaperReleasedCitations
1 Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Xiaowen Tang, Lin Yang, Zheng Li et al. · PubMed Open access 2018 412
2 Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells Fengtao You et al. · Science China Life Sciences Open access 7 Mar 2016 153
3 A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Fengtao You, Yinyan Wang, Licui Jiang et al. · PubMed Open access 2019 130
4 Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Mingzhi Zhang et al. · Clinical Cancer Research Open access 18 Apr 2022 119
5 Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma Sujun Li, Lei Xue, Min Wang et al. · OncoTargets and Therapy Open access Jul 2019 58
All 35 most cited papers, with filters and sorting

Which research topics does PersonGen (China) publish most on?

By volume in 2022-now: CAR-T cell therapy research, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research and Glioma Diagnosis and Treatment.

CAR-T cell therapy resea…2CAR-T cell therapy research: 2 fractional worksImmunotherapy and Immune…1Immunotherapy and Immune Responses: 1 fractional worksMonoclonal and Polyclona…1Monoclonal and Polyclonal Antibodies Research: 1 fractional worksGlioma Diagnosis and Treatment: 0 fractional worksImmune Cell Function and Interaction: 0 fractional worksAcute Lymphoblastic Leuk…0Acute Lymphoblastic Leukemia research: 0 fractional worksVirus-based gene therapy research: 0 fractional worksCutaneous lymphoproliferative disorders research: 0 fractional worksSemiconductor materials and devices: 0 fractional worksLung Cancer Research Studies: 0 fractional works
OncologyImmunologyRadiology, Nuclear Medicine and ImagingGenetics3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CAR-T cell therapy research Oncology 2 works
  2. 2 Immunotherapy and Immune Responses Immunology 1 works
  3. 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
  4. 4 Glioma Diagnosis and Treatment Genetics 0 works
  5. 5 Immune Cell Function and Interaction Immunology 0 works
  6. 6 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 0 works
  7. 7 Virus-based gene therapy research Genetics 0 works
  8. 8 Cutaneous lymphoproliferative disorders research Dermatology 0 works
  9. 9 Semiconductor materials and devices Electrical and Electronic Engineering 0 works
  10. 10 Lung Cancer Research Studies Oncology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available52.6%not open47.4%

World: 40% of research is openly available.

with international co-authors26.1%domestic only73.9%

World: 18% is written across borders.

How has PersonGen (China)'s research output changed?

Output in 2022-2025 was 2% higher than in 2018-2021.

still counting20052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is PersonGen (China) as a percentage of every work published that year, 0.000034% in 2024.

still counting0.000025%0.000050%0.000075%PersonGen (China)0.000052% in 202520102020

Fractional works of PersonGen (China) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Suzhou

All research institutions in Suzhou

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about PersonGen (China). Posts are plain text and can be reported.